Tentative Approvals for: Mylan Pharms Inc

« Back to Dashboard

Mylan Pharms Inc Drugs with Tentative Approvals

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Generic Name	NDA	Strength	Dosage Form
Mylan Pharms Inc	ezetimibe	201790	10MG	TABLET; ORAL
Mylan Pharms Inc	dexmethylphenidate hydrochloride	204266	5MG	CAPSULE, EXTENDED RELEASE;ORAL
Mylan Pharms Inc	quetiapine fumarate	202228	200MG	TABLET, EXTENDED RELEASE;ORAL
Mylan Pharms Inc	minocycline hydrochloride	203443	55MG	TABLET, EXTENDED RELEASE;ORAL
Mylan Pharms Inc	abacavir;lamivudine	204004	600MG;300MG	TABLET;ORAL
Applicant	Generic Name	NDA	Strength	Dosage Form

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.